中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer

文献类型：期刊论文

作者Zhao, Zi-tong4,5,6; Wang, Jue4,5; Fang, Lei4,5; Qian, Xin-di4,5; Cai, Ying4,5; Cao, Hai-qiang4,5; Wang, Guan-ru4,5; He, Mei-lin3; Jiang, Yan-yan6; Wang, Dang-ge3,4,5
刊名ACTA PHARMACOLOGICA SINICA
出版日期2022-06-15
页码11
ISSN号1671-4083
关键词nanoparticles molecular targeted therapy non-small cell lung cancer dual-responsive controlled release
DOI10.1038/s41401-022-00930-6
通讯作者Jiang, Yan-yan(yanyanjiang@fudan.edu.cn) ; Wang, Dang-ge(dgwang@simm.ac.cn) ; Li, Ya-ping(ypli@simm.ac.cn)
英文摘要The combination of vascular endothelial growth factor (VEGF) inhibitors and tyrosine kinase inhibitors (TKIs) is newly available for molecular targeted therapy against non-small cell lung cancer (NSCLC) in clinic. However, the therapeutic benefits remain unsatisfying due to the poor drug delivery to targets of interest. In this study, we developed bevacizumab-coated gefitinib-loaded nanoparticles (BCGN) with dual-responsive drug release for inhibiting tumor angiogenesis and phosphorylation of epidermal growth factor receptor (EGFR). Through an exogenous corona strategy, bevacizumab is easily coated on gefitinib-loaded nanoparticles via electrostatic interaction. After intravenous injection, BCGN are efficiently accumulated in NSCLC tumors as confirmed by dual-model imaging. Bevacizumab is released from BCGN upon oxidation in tumor microenvironment, whereas gefitinib is released after being internalized by tumor cells and disassembled in reduction cytoplasm. The dual-responsive release of bevacizumab and gefitinib significantly inhibits tumor growth in both A549 and HCC827 human NSCLC models. Our approach provides a promising strategy to improve combinational molecular targeted therapy of NSCLC with precisely controlled drug release.
WOS关键词GROWTH-FACTOR RECEPTOR ; TUMOR MICROENVIRONMENT ; DRUG-DELIVERY ; ANTI-VEGF ; COMBINATION ; PERSPECTIVE ; EXPRESSION ; STRATEGIES ; ANTITUMOR ; ERLOTINIB
资助项目National Natural Science Foundation of China[81903548] ; National Natural Science Foundation of China[32170935] ; National Natural Science Foundation of China[32070927] ; National Natural Science Foundation of China[81690265] ; National Natural Science Foundation of China[31930066] ; National Natural Science Foundation of China[82172615] ; Youth Innovation Promotion Association of CAS[2019283] ; Shanghai Sailing Program[19YF1457300] ; Shandong Provincial Natural Science Foundation[ZR2019PH013]
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
出版者NATURE PUBL GROUP
WOS记录号WOS:000811488100001
源URL[http://119.78.100.183/handle/2S10ELR8/301483]  
专题新药研究国家重点实验室
通讯作者Jiang, Yan-yan; Wang, Dang-ge; Li, Ya-ping
作者单位1.Yantai Univ, Sch Pharm, Yantai 264005, Peoples R China
2.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264000, Peoples R China
3.Yantai Inst Mat Med, Yantai Key Lab Nanomed & Adv Preparat, Yantai 264000, Peoples R China
4.Chinese Acad Sci, Ctr Pharmaceut, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
5.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
6.Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Zhao, Zi-tong,Wang, Jue,Fang, Lei,et al. Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer[J]. ACTA PHARMACOLOGICA SINICA,2022:11.
APA Zhao, Zi-tong.,Wang, Jue.,Fang, Lei.,Qian, Xin-di.,Cai, Ying.,...&Li, Ya-ping.(2022).Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer.ACTA PHARMACOLOGICA SINICA,11.
MLA Zhao, Zi-tong,et al."Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer".ACTA PHARMACOLOGICA SINICA (2022):11.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。